Insulin polysialic - Xenetic Biosciences

Drug Profile

Insulin polysialic - Xenetic Biosciences

Alternative Names: Polysialic insulin - Xenetic Biosciences; Polysialylated insulin - Xenetic/Synbio; Recombinant human insulin - Xenetic Biosciences; SuliXen; SYN20090110RU; SYN20090510RU

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipoxen Technologies
  • Developer SynBio; Xenetic Biosciences
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Small interfering RNA
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported CNS disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 24 Jul 2013 Biomarkers information updated
  • 30 Jun 2013 Phase-I clinical trials in CNS disorders in Russia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top